Raji Kit-Human Burkitt's lymphoma Cell
| Kit size Volume | Quantity | ||
|---|---|---|---|
| 4 ml(Cat-658223) | Inquiry | Add to cart | |
| 30 ml(Cat-658224) | Inquiry | Add to cart |
Product Information
Modes of administration
Electroporation Efficiency:Electroporation kit provides 75-90% delivery efficiency of siRNA. Electroporation efficiency was determined by qRT-PCR.
Description
An 11-year-old black male patient with Burkitt's lymphoma was the source of the Raji cell line, which was created in 1963. R.J.V. Pulvertaft isolated it from B-lymphocytes that were surgically taken out of the patient's body. This cell line is particularly helpful as a transfection host in molecular and cell biology studies because it is EBNA positive and has some resistance to viruses like polio and vesicular stomatitis. Raji cells are frequently employed as a model system in immunological research to examine B cell activity and to assess possible treatments for B cell-related diseases. Due to their ease of virus infection and ability to be made to make a lot of antibodies, these cells are particularly helpful for researching the immune response to viruses and other diseases. Raji cells are frequently utilized in hybridoma technology to produce monoclonal antibodies as a fusion partner. Raji cells can contribute to the development of persistent hybridomas that produce significant amounts of certain antibodies when they are united with cells that secrete antibodies, such as mouse myeloma cells.
